drugset / Trial / NCT01996826
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Phase 1/2
Completed
75 enrolled
Reza Dana, MD
Bascom Palmer Eye Institute · collabNew York Presbyterian Hospital · collabUnited States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients who are "high-risk" for rejection have blood vessels growing from the white of the eye into the cornea (clear, front region of the eye). The medication is used at the time of surgery and in the weeks following surgery. Participants have a 50/50 chance at receiving the active study medication or a placebo medication.
Timeline
- Start
- 2014-04
- Primary completion
- 2019-04
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1 % | Other |
| Comparator | Bevacizumab | Monoclonal antibody | 2.5 mg | Other |